Pharmacokinetics Study of ALO-02 and OxyContin

Completed · Phase 1

Conditions studied: Management of Moderate to Severe Pain

In brief

To characterize the single- and multiple-dose pharmacokinetics of oxycodone following the administration of ALO-02 40 Mg Twice Daily, ALO-02 80 Mg Once Daily or Oxycontin 40 Mg Twice Daily in Healthy Volunteers

Key facts

Study ID

NCT01557257

Run by

Pfizer

People needed

13

Starts

2012-03-01

Expected to finish

2012-05-01

Last updated by the study team

2012-06-28

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.

You may not qualify if…

• Evidence or history of clinically significant diseases.

Where it is running

• Pfizer Investigational Site — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.